Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
J Biol Chem ; 291(42): 21857-21868, 2016 Oct 14.
Article in English | MEDLINE | ID: mdl-27535221

ABSTRACT

The cellular form of the prion protein (PrPC) is a highly conserved glycoprotein mostly expressed in the central and peripheral nervous systems by different cell types in mammals. A misfolded, pathogenic isoform, denoted as prion, is related to a class of neurodegenerative diseases known as transmissible spongiform encephalopathy. PrPC function has not been unequivocally clarified, and it is rather defined as a pleiotropic protein likely acting as a dynamic cell surface scaffolding protein for the assembly of different signaling modules. Among the variety of PrPC protein interactors, the neuronal cell adhesion molecule (NCAM) has been studied in vivo, but the structural basis of this functional interaction is still a matter of debate. Here we focused on the structural determinants responsible for human PrPC (HuPrP) and NCAM interaction using stimulated emission depletion (STED) nanoscopy, SPR, and NMR spectroscopy approaches. PrPC co-localizes with NCAM in mouse hippocampal neurons, and this interaction is mainly mediated by the intrinsically disordered PrPC N-terminal tail, which binds with high affinity to the NCAM fibronectin type-3 domain. NMR structural investigations revealed surface-interacting epitopes governing the interaction between HuPrP N terminus and the second module of the NCAM fibronectin type-3 domain. Our data provided molecular details about the interaction between HuPrP and the NCAM fibronectin domain, and revealed a new role of PrPC N terminus as a dynamic and functional element responsible for protein-protein interaction.


Subject(s)
Hippocampus/metabolism , Neural Cell Adhesion Molecules/metabolism , Neurons/metabolism , PrPC Proteins/metabolism , Animals , Hippocampus/chemistry , Humans , Mice , Neural Cell Adhesion Molecules/chemistry , Nuclear Magnetic Resonance, Biomolecular , PrPC Proteins/chemistry , Protein Domains
2.
J Am Chem Soc ; 136(3): 937-44, 2014 Jan 22.
Article in English | MEDLINE | ID: mdl-24400836

ABSTRACT

Prions are fatal neurodegenerative transmissible agents causing several incurable illnesses in humans and animals. Prion diseases are caused by the structural conversion of the cellular prion protein, PrP(C), into its misfolded oligomeric form, known as prion or PrP(Sc). The canonical human PrP(C) (HuPrP) fold features an unstructured N-terminal part (residues 23-124) and a well-defined C-terminal globular domain (residues 125-231). Compelling evidence indicates that an evolutionary N-terminal conserved motif AGAAAAGA (residues 113-120) plays an important role in the conversion to PrP(Sc). The intrinsic flexibility of the N-terminal has hampered efforts to obtain detailed atomic information on the structural features of this palindromic region. In this study, we crystallized the full-length HuPrP in complex with a nanobody (Nb484) that inhibits prion propagation. In the complex, the prion protein is unstructured from residue 23 to 116. The palindromic motif adopts a stable and fully extended configuration to form a three-stranded antiparallel ß-sheet with the ß1 and ß2 strands, demonstrating that the full-length HuPrP(C) can adopt a more elaborate ß0-ß1-α1-ß2-α2-α3 structural organization than the canonical ß1-α1-ß2-α2-α3 prion-like fold. From this structure, it appears that the palindromic motif mediates ß-enrichment in the PrP(C) monomer as one of the early events in the conversion of PrP(C) into PrP(Sc).


Subject(s)
Prions/chemistry , Prions/metabolism , Single-Domain Antibodies/metabolism , Animals , Cell Line , Crystallography, X-Ray , Humans , Mice , Models, Molecular , Peptide Fragments/chemistry , Peptide Fragments/metabolism , Protein Binding , Protein Folding , Protein Stability , Protein Structure, Secondary
3.
Microb Cell Fact ; 11: 6, 2012 Jan 10.
Article in English | MEDLINE | ID: mdl-22233534

ABSTRACT

Expression of eukaryotic proteins in Escherichia coli is challenging, especially when they contain disulfide bonds. Since the discovery of the prion protein (PrP) and its role in transmissible spongiform encephalopathies, the need to obtain large quantities of the recombinant protein for research purposes has been essential. Currently, production of recombinant PrP is achieved by refolding protocols. Here, we show that the co-expression of two different PrP with the human Quiescin Sulfhydryl OXidase (QSOX), a human chaperone with thiol/disulfide oxidase activity, in the cytoplasm of E. coli produces soluble recombinant PrP. The structural integrity of the soluble PrP has been confirmed by nuclear magnetic resonance spectroscopy, demonstrating that properly folded PrP can be easily expressed in bacteria. Furthermore, the soluble recombinant PrP produced with this method can be used for functional and structural studies.


Subject(s)
Biotechnology/methods , Escherichia coli/metabolism , Genetic Vectors , Prions/biosynthesis , Escherichia coli/genetics , Humans , Oxidoreductases Acting on Sulfur Group Donors/genetics , Oxidoreductases Acting on Sulfur Group Donors/metabolism , Prions/genetics , Protein Disulfide Reductase (Glutathione)/genetics , Protein Disulfide Reductase (Glutathione)/metabolism , Protein Folding , Protein Structure, Tertiary , Recombinant Proteins/biosynthesis , Recombinant Proteins/genetics
4.
Protein Eng Des Sel ; 24(9): 737-41, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21536542

ABSTRACT

Prion proteins (PrPs) are difficult to crystallize, probably due to their inherent flexibility. Several PrPs structures have been solved by nuclear magnetic resonance (NMR) techniques; however, only three structures were solved by X-ray crystallography. Here we combined in-situ proteolysis with automated microseed matrix screening (MMS) to crystallize two different PrP(C)-nanobody (Nb) complexes. Nanobodies are single-domain antibodies derived from heavy-chain-only antibodies of camelids. Initial crystallization screening conditions using in-situ proteolysis of mouse prion (23-230) in complex with a nanobody (Nb_PrP_01) gave thin needle aggregates, which were of poor diffraction quality. Next, we used these microcrystals as nucleants for automated MMS. Good-quality crystals were obtained from mouse PrP (89-230)/Nb_PrP_01, belonged to the monoclinic space group P 1 21 1, with unit-cell parameters a = 59.13, b = 63.80, c = 69.79 Å, ß = 101.96° and diffracted to 2.1 Å resolution using synchrotron radiation. Human PrP (90-231)/Nb_PrP_01 crystals belonged to the monoclinic space group C2, with unit-cell parameters a = 131.86, b = 45.78, c = 45.09 Å, ß = 96.23° and diffracted to 1.5 Å resolution. This combined strategy benefits from the power of the MMS technique without suffering from the drawbacks of the in-situ proteolysis. It proved to be a successful strategy to crystallize PrP-nanobodies complexes and could be exploited for the crystallization of other difficult antigen-antibody complexes.


Subject(s)
Antigen-Antibody Complex/chemistry , Crystallization/methods , Prions/chemistry , Animals , Antigen-Antibody Complex/metabolism , Crystallography, X-Ray , Electrophoresis, Polyacrylamide Gel , Humans , Mice , Peptide Fragments/chemistry , Peptide Fragments/metabolism , Prions/metabolism , Proteolysis
5.
Acta Crystallogr Sect F Struct Biol Cryst Commun ; 66(Pt 12): 1644-6, 2010 Dec 01.
Article in English | MEDLINE | ID: mdl-21139215

ABSTRACT

Prion disorders are infectious diseases that are characterized by the conversion of the cellular prion protein PrPC into the pathogenic isoform PrPSc. Specific antibodies that interact with the cellular prion protein have been shown to inhibit this transition. Recombinant VHHs (variable domain of dromedary heavy-chain antibodies) or nanobodies are single-domain antibodies, making them the smallest antigen-binding fragments. A specific nanobody (Nb_PrP_01) was raised against mouse PrPC. A crystallization condition for this recombinant nanobody was identified using high-throughput screening. The crystals were optimized using streak-seeding and the hanging-drop method. The crystals belonged to the orthorhombic space group P2(1)2(1)2(1), with unit-cell parameters a=30.04, b=37.15, c=83.00 Å, and diffracted to 1.23 Šresolution using synchrotron radiation. The crystal structure of this specific nanobody against PrPC together with the known PrPC structure may help in understanding the PrPC/PrPSc transition mechanism.


Subject(s)
Antibodies/chemistry , Prions/chemistry , Prions/immunology , X-Ray Diffraction , Animals , Chromatography, Gel , Crystallization , Crystallography, X-Ray , Mice , Prion Proteins , Protein Structure, Tertiary , Synchrotrons
SELECTION OF CITATIONS
SEARCH DETAIL
...